Asia Pacific Epigenetics Market – Size, Trends and Forecast (2024 – 2032)

Epigenetics is a stream of genetics that involves the genetic development of an organism, especially the activation and deactivation of genes without changing its gene expression. An epigenetic change is natural and also influences the factors such as lifestyle and age. In-depth research on epigenetics has discovered human disorders and diseases.

The Asia Pacific Epigenetic Market Segments Size & Growth:

The Asia Pacific Epigenetic Market is accounted for $4 billion in 2017 and expected to grow at a CAGR of 32% to reach $13.2 billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth owing to the increase in some cases of cancer; rise in investments and funds, and emerging various applications. However, high cost for epigenetic therapies, misinterpretation of genetic data, and lack of reimbursement hinder the growth of the epigenetics market.

The Asia Pacific Epigenetic Market SegmentsShare:

The Asia PacificEpigenetic Market is categorised into by type product which consists of reagents, kits, enzymes, and instruments. Kits have the most significant share due to the increased usage of kits in epigenetic techniques.  By technology, the epigenetic market is segmented as RNA interference, DNA methylation, and histone modifications. Among all DNA methylation are expected to have high growth rate during the forecast period 2018-2024, because of increase in cancer cases and the ability of epigenetics to treat cancer cells.Biotechnology and contract research organisation are leading in the epigenetic market among end users owing to the rise in technological advancements, research, and manufacturing of precision medicine.

By Geography, China is dominating the epigenetic market, and the growth in the Asia Pacific is mainly attributed because of the increasing demand for personalised medicine and rise in cancer cases. Furthermore, India is witnessing the fastest growth during the forecast period, due to rising ageing population, chronic diseases and investment in R&D research.

The Asia Pacific Epigenetic Market SegmentsTrends:

• In a recent study on epigenetics, some epigenetic pharmaceuticals have the potential to be used as antivirals.
• In January 2017, Delinia, Inc. has been merged along with Celgene Corporation to produce new therapeutics for autoimmune diseases.

The Asia Pacific Epigenetic Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and the global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• Celgene
• 4SC
• Merck Millipore
• Karus Therapeutics
• Ribimed Biotechnologies